Veracyte Breakfast Symposium – The New Afirma Genomic Sequencing Classifier – Leveraging Enriched Genomic Data through RNA Sequencing and Advancements in Machine Learning to Identify More Benign Thyroid Nodules

     

    The New Afirma Genomic Sequencing Classifier – Leveraging Enriched Genomic Data through RNA Sequencing and Advancements in Machine Learning to Identify More Benign Thyroid Nodules

    Date: Sunday, July 30th
    Time: 6:00 am – 7:30 am
    Location: Marina Ballroom

    Speakers:

    • Giulia C. Kennedy, Chief Scientific Officer and Senior Vice President of Research and Development, Veracyte
    • Richard T. Kloos, Senior Medical Director, Endocrinology, Veracyte
    • Plus, an expert clinician guest speaker

    This special presentation will provide an in-depth overview of Veracyte’s next-generation Afirma Genomic Sequencing Classifier (GSC). The event will cover the following learning objectives:

    • Discuss scientific development of the Afirma GSC
    • Review Afirma GSC validation results
    • Illustrate impact of Afirma GSC’s improved test performance
      –  Increase benign results by >30% to further reduce unnecessary surgeries
      –  Increase prevalence of cancer in Afirma GSC Suspicious cases

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts